Achiever's Success Story
Impacting lives of the Cancer patients
She was born and raised in Madurai, India, with military discipline background. In her early 1990’s along with life challenges managed to graduate with a bachelor’s degree when computers, MBBS degree education was affordable only to rich background Indians. Further, she was highly motivated to learn about DNA and protein biotechnology methods from Madurai Kamaraj University. After that, in her mid-20s, with a curiosity to learn molecular biology and cell biology, she was lucky to step into her dream job, CCMB govt of India. In her early 40s, with young children struggles pursued her PhD at Curtin University in Perth, Western Australia, in a fully funded scholarship and family sponsorship under the supervision of Dr Simon Fox and Prof. Arun Dharmarajan collaborative project.
With minimal supervision she graduated, contributing to the role of the SFRP4 in the modulation of cancer growth and antineoplastic drug sensitivity with seven (highest number) peer-reviewed publications accomplishments. In applying her previous expertise completed small projects task at UWA on Ciliary neurotrophic factor (CNTF) lentiviral gene delivery and Curtin University in collaboration with Oxford University, studying the role of SFRP4 domains and peptides in GBM, Ovary and Prostate cancer stem cells.
Over the past twelve years she carried out basic and clinical research, working closely on collaborations. Discoveries made during basic research on SFRP4 led to targeting cancer stem cells. She aimed to bring in new generation cutting edge technologies that could target viable cancer cell spheres in the blood. In her recent 2017 clinical research fellow role as a chief investigator with merit appointments, she discovered 150 billion USD market scope blood testing by counting and culturing viable circulating tumour cells (CTC) and spheres for radiotherapy medicine and SFRP4 treatments. Combining her early cancer detection serendipitous discovery with doctoral research developed new SFRP4 drug screening blood testing for the broader societal impact in the cancer risk population. She strongly believes in her discoveries to open avenues catching solid tumours early for human cell protein therapeutics. Beyond her proven lead role in securing 448 000 AUD value project funds provided scientific leadership with new ideas in an international business model for SFPR4 CTC genomics medicine. Combining her previous collaborative employments with Sir Charles Gairdner Hospital, Curtin University, Oxford University and UWA research skills with twelve years of the Australian lifestyle, she will be a global asset for world-class innovative technologies impacting cancer health care.
She is grateful to her senior mentors, supervisors, and colleagues for supporting the research journey success. She combines govt hospital clinical research excellence business model by reducing toxicity for more effective drugs treatments. She looks forward to using her education and research skills resources to motivate other family women through her business model. She envisions changing longer-term future blood diagnostics opportunities globally for a sustainable economy in curing this complex disease by cutting the cost of ineffective drugs outside the patient for transforming cancer patients’ life.